RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 ICE: No Advantage to Adding Capecitabine to Ibandronate in High-Risk Early BC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 56
SP 9
OP 9
DO 10.1177/1559897715571069
UL http://mdc.sagepub.com/content/14/56/9.abstract
AB Previous studies suggested that elderly patients with early moderate- to high-risk breast cancer might benefit from adjuvant combination capecitabine plus ibandronate. The phase 3 ICE study showed no difference in invasive disease-free survival or overall survival at 3 or 5 years between those receiving capecitabine plus ibandronate vs ibandronate alone.